Valerie Oriol Mathieu is Global Medical Affairs Leader, Vaccines. In her role, Valerie is the Medical Affairs Lead for the licensed Janssen vaccines and the vaccine portfolio in R&D. Valerie is a Medical Doctor, holds a Masters in strategic management, and Vaccinology degrees. After a few years of clinical practice, she worked for contract research organizations, focusing on late clinical development and post-marketing studies. In 2006, Valerie joined the vaccine industry within Medical Affairs where she worked in the field of enteric diseases, influenza and travel vaccines. She later moved to Scientific Affairs, and finally she evolved to Policy responsibilities.

For more than 5 years, Valerie has worked with Janssen Vaccines as Director Global Vaccines Policy and Partnership where she was responsible for policy strategy for candidate vaccines in development at Janssen in the field of respiratory diseases, HIV, Ebola and Extra-intestinal E.coli. In her role she has been analyzing global societal and political perspectives on public health, related to the prevention of infectious diseases through vaccination. She has developed Janssen positions on vaccine policies in order to serve Janssen reputational and business objectives. She led Janssen representation in several vaccine working groups with trade associations, public health authorities, international coalitions and expert groups. She is a founding member of VaccinesToday.eu, with expertise in knowledge sharing from high level vaccinology education to social media conversation with lay public.

In 2016, she became Global Medical Affairs Leader for Vaccines, responsible for optimizing development and use of our vaccines through qualitative and compliant engagement with medical community. She leads disseminating science, understanding medical needs, contributing to clinical development plans for late phases and post-licensure evaluation (health outcomes, real world data), preparing for vaccine program implementation in countries with a focus on platform technologies, emerging diseases and HIV. She is part of the Good Participatory Practices team, and involved in public-private interactions for development and access projects (e.g. IMI projects).